ArticleLasers in medical science2025
Evaluation of laser-photobiomodulation different irradiation parameters on macrophages (RAW 264.7) inflammatory mediators' production.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A stalactite-inspired NIR/pH-responsive visualizable nano-platform for microenvironment-activated therapy of peri-implantitis-induced bone defects.Bioactive materials · 2026Article
- Modulation of resting macrophage activity via low-level laser therapy (LLLT) and α-lipoic acid: an in vitro study using a PCL-based biomaterial.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMacrophages are pivotal cells in the inflammatory process, and their functions can be modulated by laser irradiation. However, there is no consensus in the literature about Laser-photobiomodulation (L-PBM) parameters that are more suited to stimulate or inhibit them. The goal of this research is to contribute to the understanding of the effects of different L-PBM protocols on inflammatory mediators' production/inhibition and cell viability of macrophage cells in vitro. MATERIALS AND
methodsThe macrophages cells (RAW 264.7) were divided into two groups: LPS-stimulated (Lipopolysaccharide from Escherichia coli) and non-LPS-stimulated. Each group was subdivided into non-irradiated and irradiated groups. The irradiated group was further divided into: 660 nm, 1 J, 10s; 660 nm, 2 J, 20s; 660, 3 J, 30s; 808 nm 1 J, 10s; 808 nm, 2 J, 20s; 808, 3 J, 30s groups. To all groups and subgroups, a negative (non-irradiated) group was added. All groups and subgroups were evaluated for cell viability, Nitric oxide (NO), interleukin-6 (IL-6) and Tumor Necrosis Factor- α (TNF-α) production.
resultsThe results indicated that macrophages irradiated at 660 nm and 808 nm, operating in 1 J, 10s; 2 J, 20s and 3 J, 30s did not change NO, TNF-α and IL-6 production nor cell Viability in non-LPS groups. However, in LPS-stimulated macrophages, a significant stimulatory effect on NO production was observed after laser-irradiation with 660 nm for 2 J, 20s. This NO-stimulatory effect was not observed in the 880 nm irradiated group. LPS-activated macrophages and L-PBM irradiation at 660 nm and 808 nm also resulted in significant inhibitory effects on TNF-α and IL-6 production after 2 J, 20s irradiation. However, TNF-α and IL-6 inhibition using 1 J, 10s was achieved only in 660 nm group.
conclusionOur findings suggested that, if other parameters are fixed, time and related fluence/energy delivery are important dimensions to consider in L-PBM-production/inhibition on the inflammatory mediators tested. The NO synthesis was more prone to be modulated by a specific wavelength (660 nm) and a broader time-range inhibition of TNF-α and IL-6 was observed in 660 nm groups. Cell viability was not changed in any parameter tested.
Indexed as
Identifiers
40965692What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.